News & Updates

Cholinesterase inhibitors show promise for treating gait disturbance in PD

07 Dec 2021

Treatment with cholinesterase inhibitors in patients with Parkinson’s disease (PD) leads to significant improvements in gait variability, with trending benefits for gait speed and fall prevention, according to the results of a meta-analysis.

Cholinesterase inhibitors show promise for treating gait disturbance in PD

07 Dec 2021

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021 by

Switching to tenofovir alafenamide (TAF) from nucleos(t)ide analogue therapies was associated with improved virologic response and liver function in patients with chronic hepatitis B virus (HBV) infection, even in those with decompensated HBV cirrhosis, according to real-world studies presented at AASLD 2021.

Switching to TAF helps improve virologic response in HBV patients in real world

06 Dec 2021

Birth control pills pose inflammatory bowel disease risk

06 Dec 2021 by

The use of combined oral contraceptive pills (COCPs) appears to confer some risk of inflammatory bowel disease, which increases accordingly with duration of COCP exposure, as shown in a study.

Birth control pills pose inflammatory bowel disease risk

06 Dec 2021

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021 by

The pan-PPAR* agonist lanifibranor further advances into the NASH** treatment field, as more data from the phase IIb NATIVE*** study presented at AASLD 2021 unveil further histologic and therapeutic benefits for patients with NASH.

Interim findings boost therapeutic potential of lanifibranor for NASH

06 Dec 2021

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

06 Dec 2021

In the second-line treatment of patients advanced oesophageal cancer, the use of programmed cell death 1 (PD-1) inhibitors yields more favourable outcomes than chemotherapy across multiple patient subgroups, according to the results of a meta-analysis.

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

06 Dec 2021

Original New Drug Application Approvals by US FDA (16 - 30 November 2021)

06 Dec 2021

New drug applications approved by US FDA as of 16-30 November 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 30 November 2021)

06 Dec 2021

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021 by

The SGLT2i* canagliflozin significantly improves symptoms and quality of life (QoL) early on during treatment in people with heart failure (HF) due to either reduced or preserved ejection fraction (rEF or pEF), regardless of whether they have type 2 diabetes (T2D), according to the CHIEF-HF** study presented at AHA 2021.

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

04 Dec 2021

Actual body weight dosing of temozolomide offers survival benefits in glioblastoma

03 Dec 2021

Temozolomide administered to patients with glioblastoma at full actual body weight dosing during the concurrent phase is necessary to achieve a median overall survival (OS) that is similar to that seen in a previous trial, according to a recent study.

Actual body weight dosing of temozolomide offers survival benefits in glioblastoma

03 Dec 2021

Steroid-free remission in Crohn’s disease does not equate to less progression

03 Dec 2021

For Crohn’s disease patients, achieving a complete and sustained clinical remission off steroids does not necessarily translate to a lower likelihood of experiencing progression, according to data from the TAILORIX trial.

Steroid-free remission in Crohn’s disease does not equate to less progression

03 Dec 2021

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021 by

Treatment with inclisiran consistently reduced low-density lipoprotein cholesterol (LDL-C) levels in patients with, or at high risk of, atherosclerotic cardiovascular disease (ASCVD), regardless of glycaemic status, based on a pooled analysis of the ORION-10* and ORION-11** studies presented at AHA 2021.

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

03 Dec 2021

News & Updates

Filter by Specialty:

Specialty:

Cholinesterase inhibitors show promise for treating gait disturbance in PD

Cholinesterase inhibitors show promise for treating gait disturbance in PD

Switching to TAF helps improve virologic response in HBV patients in real world

Switching to TAF helps improve virologic response in HBV patients in real world

Birth control pills pose inflammatory bowel disease risk

Birth control pills pose inflammatory bowel disease risk

Interim findings boost therapeutic potential of lanifibranor for NASH

Interim findings boost therapeutic potential of lanifibranor for NASH

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

PD-1 inhibitors outperform chemo in second-line treatment of advanced oesophageal cancer

Original New Drug Application Approvals by US FDA (16 - 30 November 2021)

Original New Drug Application Approvals by US FDA (16 - 30 November 2021)

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Canagliflozin improves HF symptoms, QoL regardless of diabetes status

Actual body weight dosing of temozolomide offers survival benefits in glioblastoma

Actual body weight dosing of temozolomide offers survival benefits in glioblastoma

Steroid-free remission in Crohn’s disease does not equate to less progression

Steroid-free remission in Crohn’s disease does not equate to less progression

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD

Inclisiran sustains LDL-C reduction in high-risk patients with ASCVD